الصفحة الرئيسية>>Signaling Pathways>> Neuroscience>> Ophthalmology>>Tafluprost ethyl amide

Tafluprost ethyl amide (Synonyms: Taf EA, Tafluprost EA)

رقم الكتالوجGC18573

تافلوبروست إيثيل أميد مشتق من البروستاغلاندين.

Products are for research use only. Not for human use. We do not sell to patients.

Tafluprost ethyl amide التركيب الكيميائي

Cas No.: 1185851-52-8

الحجم السعر المخزون الكميّة
1mg
144٫00
متوفر
5mg
643٫00
متوفر
10mg
1139٫00
متوفر
25mg
2491٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products
Tafluprost ethyl amide is derived from 17-phenyl trinor Prostaglandin F2α(17-phenyl trinor PGF2α). A number of 17-phenyl trinor PGF2α derivatives have been approved for the treatment of glaucoma. Of these, the ones wherein the 13,14-double bond has been hydrogenated retain relatively good potency, but show a significantly reduced incidence of local irritant side effects. Alternatively, it was recently reported that analogs incorporating a 15-deoxy-15,15-difluoro modification also had a favorable ophthalmic activity profile. Tafluprost is a 2-series, 16-phenoxy analog of PGF2α with the 15,15-difluoro substitution. As a free acid, Tafluprost is a very potent FP receptor agonist (Ki = 0.4 nM). Ethyl amides of PGs tend to increase lipid solubility, to improve uptake into tissues and to further lower the effective concentration.

مراجعات

Review for Tafluprost ethyl amide

Average Rating: 5 ★★★★★ (Based on Reviews and 9 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Tafluprost ethyl amide

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.